Skip to content Skip to footer
Subscribe Now
Abbvie
NEWS

AbbVie Reports Topline P-II (ELATE) Trial Data on Botox (OnabotulinumtoxinA) for Upper Limb Essential Tremor

Shots: AbbVie has reported topline P-II (ELATE) trial data assessing Botox (onabotulinumtoxinA) vs PBO in pts with upper limb essential tremor Trial met its 1EP with improved Tremor Disability Scale-Revised scores at 18wks. & showed a greater TREDS-R total unilateral score reduction (-2.61 vs -1.61), plus it also achieved all six 2EPs; data to be…
October 7, 2025

Read more

VIEWPOINTS_Rui Avelar_2023
VIEWPOINTS

Rui Avelar, CMO and Head of R&D at Evolus Shares Insights from Interim P-II Data Results Evaluating an “Extra-Strength” Formulation of Jeuveau

Shots: Rui gave the details about the “extra-strength” formulation of Jeuveau. He highlighted the study design and results of the trial evaluating  Jeuveau. The data indicated that the “extra-strength” formulation of Jeuveau at 40U achieved a duration profile of 6 months or 26 weeks The data was presented at the 2023 IMCAS World Congress in…
June 13, 2023

Read more